Cannabis Law Report

SEPTEMBER 13, 2021

(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it intends to initiate dosing for a Phase 2 trial of MYMD-1’s function in delaying aging early in the fourth quarter of 2021. For more information, visit www.mymd.com. in the blood.

Clinical Trials 52

Clinical Trials Pharmaceutical Research and Development Therapy 52

MMJ Recs

MAY 9, 2024

Many veterans struggle with various physical and psychological conditions resulting from their service. These professionals can provide valuable insights into whether medical cannabis is a suitable option based on the veteran’s medical history, current conditions, and treatment goals.

Research and Development 52

Research and Development Therapy Clinical Trials Treatment 52

Cannabis Law Report

SEPTEMBER 9, 2021

MYMD-1 is also being developed as a potential therapy for COVID-19-related conditions such as post-COVID-19 syndromes. Supera-CBD is being developed to address anxiety, chronic pain, addiction, and seizures, and is on a path toward human clinical trials as a therapy for epilepsy, followed by chronic pain.

Pharmaceutical 97

Pharmaceutical Clinical Trials Chronic Pain Epilepsy 97

Veriheal

SEPTEMBER 6, 2022

Some people turn to cannabis to help them manage the symptoms of mild pain and inflammation. Others use cannabis to help manage chronic pain. ” The review also found that synthetic cannabinoids such as nabilone may help reduce nightmares associated with PTSD and potentially improve sleep among patients with chronic pain.

Sleep 105

Sleep THC CBD Chronic Pain 105

Cannabis Law Report

JUNE 21, 2021

RYAH publishes monthly reports discussing various topics arising from their analysis of the reams of data in its proprietary RYAH Cloud database, offering a glimpse of how the information can be used. The most recent one , from June 2021, takes a look at patients using cannabis to relieve pain.

Data 105

Data Clinical Trials Research and Development Indica 105

Cannabis Law Report

JANUARY 12, 2022

. “Gb Sciences has established a pipeline of patent-protected combination therapies for the treatment of medical conditions affecting hundreds of millions of people,” said Dr. Andrea Small-Howard, President and Chief Science Officer of Gb Sciences. ” Gb Sciences’ intellectual property portfolio includes five U.S.

Research and Development 52

Research and Development Clinical Trials Chronic Pain Therapy 52

Veriheal

MAY 3, 2022

The team sought to answer the following: “What are the risks and benefits of obtaining a medical marijuana card for adults who seek medical marijuana for pain, insomnia and anxiety or depressive symptoms?”—a Clinical Trial Sample Size. Missing Information. Daily Cannabis Use as a Disqualifier.

Research and Development 98

Research and Development Clinical Trials Consumption Patients 98

Project CBD

MAY 3, 2023

She is the medical director of Canna-Centers Wellness & Education and the clinical advisor to Cannformatics. She is also the author of Cannabis is Medicine: How Medical Cannabis and CBD are Healing Everything from Anxiety to Chronic Pain. CannMed: For what conditions do you think CBG has the most promise?

Cannabinoids 209

Cannabinoids Sleep Clinical Trials CBD 209

Cannabis Law Report

JUNE 8, 2021

This SRA will leverage four other clinical trials being planned by the university, to determine the effects of psilocybin on inflammatory markers of patients who have exhibited Parkinson’s, Bipolar disorder, and chronic back pain. For more information, visit www.silopharma.com.

Patients 92

Patients Research and Development Clinical Trials Chronic Pain 92

Cannabis Law Report

AUGUST 24, 2021

The Company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction and epilepsy. For more information, visit www.mymd.com. Cautionary Statement Regarding Forward-Looking Statements. Investor Contact: Robert Schatz. 646) 421-9523. rschatz@mymd.com www.mymd.com.

Pharmaceutical 98

Pharmaceutical Clinical Trials Chronic Pain CBD 98

Cannabis Law Report

DECEMBER 28, 2021

The users of CBD products claim to have seen improvement in different medical conditions, including depression, chronic pain, insomnia, epilepsy, anxiety, etc., But despite the growing popularity of CBD items, various myths surround this product that make it difficult for some individuals to make an informed decision.

CBD 52

CBD Clinical Trials Consumption Chronic Pain 52

MMJ Recs

DECEMBER 22, 2023

Surveys and polls consistently show a majority of Americans supporting medical marijuana, reflecting a more informed and open-minded approach to its potential benefits. Studies have shown the efficacy of medical cannabis in treating conditions such as chronic pain, epilepsy, and certain mental health disorders.

Marijuana 52

Marijuana Chronic Pain Advocacy Research and Development 52

Cannabis Law Report

OCTOBER 5, 2021

The Company’s second drug platform, Supera-CBD , is being developed to treat chronic pain, addiction and epilepsy. For more information, visit www.mymd.com. Cautionary Statement Regarding Forward-Looking Statements. Investor: Robert Schatz. 646) 421-9523. rschatz@mymd.com www.mymd.com. Media: media@mymd.com.

Pharmaceutical 52

Pharmaceutical Clinical Trials Chronic Pain Media 52

Cannabis Law Report

NOVEMBER 24, 2019

Finding more information and committee details. Chronic pain. People have the right to be involved in discussions and make informed decisions about their care, as described in your care. People have the right to be involved in discussions and make informed decisions about their care, as described in your care.

Medicine 59

Medicine Chronic Pain Research and Development Treatment 59

Cannabis Law Report

OCTOBER 19, 2021

The Company believes that Supera-CBD is currently on a path toward human clinical trials as a therapy for epilepsy, followed by chronic pain. The Company’s second drug platform, Supera-CBD , is being developed to treat chronic pain, addiction and epilepsy. For more information, visit www.mymd.com.

Pharmaceutical 52

Pharmaceutical Therapy Clinical Trials Chronic Pain 52

CannaMD

SEPTEMBER 9, 2020

Published only recently, in May of 2020, this clinical trial is the first to show that microdoses of cannabis can be just as effective as much higher doses. They gave 27 patients with chronic pain (reporting pain levels of at least six out of 10) one of the following treatment options: 5mg of inhaled THC.

Microdosing 111

Microdosing Marijuana Clinical Trials Chronic Pain 111

Cannabis Law Report

DECEMBER 1, 2021

The Company believes that Supera-CBD is currently on a path toward human clinical trials as a therapy for epilepsy, followed by chronic pain. The Company’s second drug platform, Supera-CBD , is being developed to treat chronic pain, addiction and epilepsy. For more information, visit www.mymd.com.

Pharmaceutical 52

Pharmaceutical Clinical Trials Chronic Pain Therapy 52

Veriheal

JULY 12, 2021

As a veteran, being able to get past the PTSD involves transitioning out of the mental and emotional war zone, which is challenging and the reason why veterans seek out multiple methods to deal with the condition. Veterans can expect to find conflicting information regarding the efficacy of cannabis for their PTSD.

Treatment 104

Treatment Sleep Clinical Trials Data 104

Cannabis Law Report

DECEMBER 29, 2021

The company has received clearance from the South African Health Products Regulatory Authority to begin patient enrollment in a first-in-human clinical trial and preparations to begin that trial are underway. Oravax is also preparing to commence clinical trials in Israel. For more information, visit www.mymd.com.

Pharmaceutical 52

Pharmaceutical Clinical Trials Chronic Pain CBD 52

Cannabis Law Report

AUGUST 2, 2021

Study Results Indicate SCI-160 Has A Significant Analgesic Effect on Acute and Chronic Pain. Key findings from the pre-clinical trial are as follows: SCI-160 significantly alleviates pain up to 6 hours after injection as compared with vehicle-treated animals. TEL AVIV, Israel , Aug. Logo – [link].

Research and Development 105

Research and Development Clinical Trials Treatment Pharmaceutical 105

Cannabis Law Report

SEPTEMBER 9, 2021

Medical cannabis is used for the treatment of various chronic conditions, such as Parkinson’s disease, Alzheimer’s disease, arthritis, cancer, depression, anxiety, epilepsy, and other neurological conditions. Global Legal Cannabis Industry: Number of Clinical Trials, By Region. Chronic Pain.

Recreational 95

Recreational Hemp THC Legalization 95

Cannabis Law Report

NOVEMBER 18, 2021

“Oravax has received clearance from the South African Health Products Regulatory Authority to begin patient enrollment in a first-in-human clinical trial for its oral COVID-19 vaccine, and preparations to begin the trial are underway. Oravax is also preparing to commence clinical trials in Israel.”. 646) 421-9523.

Pharmaceutical 52

Pharmaceutical Clinical Trials Business Chronic Pain 52

Cannabis Law Report

SEPTEMBER 22, 2021

At 8,000 times the potency of regular CBD, we believe that Supera-CBD shows strong potential as a therapeutic for high-threat diseases and conditions like Alzheimer’s, psychosis, neuropathic pain, addiction, and anxiety. For more information, visit www.mymd.com. Chris Chapman, M.D., About MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Data CBD Clinical Trials 52

Cannabis Law Report

SEPTEMBER 14, 2021

Those insights will help bring products to market that are specifically formulated based on rigorous evidence to address need states like chronic pain, restful sleep, and general health and well-being. For more information, visit [link] and follow their LinkedIn page. About Radicle Science.

Extraction 52

Extraction Research and Development Clinical Trials CBD 52

MMJ Recs

JUNE 15, 2022

Medical marijuana (MMJ) is used to treat pain from a wide variety of conditions or illnesses, including everything from chronic back pain to arthritis. There are many treatments that can be utilized along with MMJ products to alleviate pain, such as medications, physical therapy, and massage.

Patients 52

Patients Treatment Clinical Trials Therapy 52

The Cannigma

JANUARY 13, 2023

Migraines are a peculiarly painful condition. In fact, migraine is now ranked as the second leading cause of years lived with disability, following only lower back pain. Scientists still don’t understand exactly why migraines happen, nor how to cure the condition – but perhaps cannabis can help.

Terpenes 132

Terpenes Strains THC Treatment 132

Cannabis Law Report

OCTOBER 26, 2021

MyMD plans to advance MYMD-1 in the clinic with two simultaneous Phase 2 trials beginning in the current quarter, one for delaying aging and prolonging healthy lifespan, and the second for COVID-19-associated depression and cytokine elevation. For more information, visit www.mymd.com. Dr. Chapman Bio. MyMD: Robert Schatz.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

OCTOBER 22, 2021

The increasing research on medical marijuana shows its therapeutic value for a range of health conditions, including chronic pain, cancer, arthritis, diabetes, depression, anxiety, and many more. For more information about this drug pipelines report visit [link]. Medical Marijuana – Cannabidiol Understanding.

Research and Development 52

Research and Development Pharmaceutical Marijuana Chronic Pain 52

CannaTech

SEPTEMBER 16, 2018

These guidelines outline a list of qualifying conditions that patients must possess in order to legally obtain medical cannabis. Many healthcare practitioners possess a knowledge gap about cannabis, as their medical school curriculum didn’t include any information on the topic.

Education 66

Education Medicine Clinical Trials Patients 66

Cannabis Law Report

NOVEMBER 16, 2021

As cleared by the FDA, the primary endpoint of the Phase 2 double-blind, placebo-controlled clinical trial is to achieve a reduction in the circulating levels of tumor necrosis factor-alpha (TNF-?), The Company’s second drug platform, Supera-CBD , is being developed to treat chronic pain, addiction and epilepsy.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Healer

DECEMBER 17, 2021

Drug interactions reported in the scientific literature most often occur at very high doses used in clinical trials of epilepsy and other conditions. Based on my clinical experience, it is rare for people to experience CBD-drug interactions at doses below 100mg daily. . How Do CBD Drug Interactions Occur?

CBD 98

CBD THC Conditions Medicine 98

Cannabis Law Report

NOVEMBER 23, 2021

The Company’s second drug platform, Supera-CBD , is being developed to treat chronic pain, addiction and epilepsy. For more information, visit www.mymd.com. Cautionary Statement Regarding Forward-Looking Statements. MyMD Contact: Robert Schatz. 646) 421-9523. rschatz@mymd.com www.mymd.com.

Pharmaceutical 52

Pharmaceutical Clinical Trials Therapy Chronic Pain 52

Puff Puff Post

SEPTEMBER 16, 2019

” As Québec’s first and foremost medical cannabis clinic and research centre, Santé Cannabis has received referrals from more than 2,500 physicians and assessed over 6,000 patients since 2014, while also providing information sessions for patients and healthcare professionals. ABOUT SPECTRUM THERAPEUTICS.

Programs 108

Programs Research and Development Education Treatment 108

TheAnswerPage

JANUARY 11, 2022

As reviewed in a recent Forbes article, “a study of more than 400 health care professionals has revealed that most physicians lack knowledge of medicinal cannabis, with 65% saying that they have been asked about medical marijuana as a treatment for chronic pain but were unable to answer their patients’ questions” (1).

Patients 98

Patients Education Marijuana Therapy 98

Cannabis Law Report

JULY 4, 2021

Clinical trials across the EU have also shown CBD oils and other hemp products to have a potential range of benefits. Today, people use CBD products to help with various medical conditions, such as diabetes, Chron’s disease, multiple sclerosis, and arthritis. Now we come to CBD. Final Note.

THC 105

THC CBD Legalization Oil 105

Cannabis Law Report

JANUARY 5, 2022

The Company’s second drug platform, Supera-CBD , is being developed to treat chronic pain, addiction and epilepsy. For more information, visit www.mymd.com. Cautionary Statement Regarding Forward-Looking Statements. 2 Goates et al. 3 Koon Yee-Lee et al. 4 [link].

Pharmaceutical 52

Pharmaceutical Clinical Trials Therapy Treatment 52

Cannabis Law Report

JANUARY 24, 2022

The CBD segment dominated the market in 2021 due to the growing awareness about the positive effects of CBD for the treatment of various medical conditions, such as chronic pain, cancer & multiple sclerosis. Growing adoption of medical marijuana for treatment of chronic diseases. Chronic Pain.

Legalization 52

Legalization Supply Chain Chronic Pain Recreational 52